

1 **Influenza virus shedding and symptoms: Dynamics and implications from a multi-season**
2 **household transmission study**

3 Sinead E. Morris, PhD^{1,2,*}, Huong Q. Nguyen, PhD, MPH³, Carlos G. Grijalva, MD, MPH⁴, Kayla E. Hanson,
4 MPH³, Yuwei Zhu, MD, MS⁴, Jessica E. Biddle, MPH¹, Jennifer K. Meece, PhD³, Natasha B. Halasa, MD,
5 MPH⁴, James D. Chappell, MD, PhD⁴, Alexandra M. Mellis, PhD², Carrie Reed, DSc, MPH¹, Matthew
6 Biggerstaff, ScD, MPH¹, Edward A. Belongia, MD³, H. Keipp Talbot, MD, MPH⁴, Melissa A. Rolfes, PhD,
7 MPH¹

8 ¹Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA

9 ²Goldbelt Professional Services, Chesapeake, VA, USA

10 ³Marshfield Clinic Research Institute, Marshfield, WI, USA

11 ⁴Vanderbilt University Medical Center, Nashville, TN, USA

12

13 ***Corresponding author:** Sinead Morris, run7@cdc.gov, Centers for Disease Control and Prevention, 1600
14 Clifton Rd NE, Atlanta, GA, 30033

15

16 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
17 represent the views of the Centers for Disease Control and Prevention.

18

19 **Competing Interest Statement:** H.Q.N receives research support unrelated to this work from CSL
20 Seqirus and GSK, and honorarium for participating in a consultancy group for Moderna outside the
21 submitted work. C.G.G received research support unrelated to this work from Merck. K.E.H, J.K.M, and
22 E.A.B receive research support unrelated to this work from CSL Seqirus. The authors have no competing
23 interests to declare.

24

25 **Keywords:** seasonal influenza; virus shedding; symptom severity; transmission dynamics; household
26 study

27

28

29

30

31

32

33

34

35 **Abstract**

36 Isolation of symptomatic infectious persons can reduce influenza transmission. However, virus shedding
37 that occurs without symptoms will be unaffected by such measures. Identifying effective isolation
38 strategies for influenza requires understanding the interplay between individual virus shedding and
39 symptom presentation. From 2017–2020, we conducted a case-ascertained household transmission
40 study using influenza real-time reverse transcription quantitative PCR (RT-qPCR) testing of nasal swabs
41 and daily symptom diary reporting for up to 7 days after enrollment (≤ 14 days after index onset). We
42 assumed real-time RT-qPCR cycle threshold (Ct) values were indicators of quantitative virus shedding
43 and used symptom diaries to create a score that tracked influenza-like-illness (ILI) symptoms (fever,
44 cough, or sore throat). We fit phenomenological nonlinear mixed-effects models stratified by age and
45 vaccination status and estimated two quantities influencing isolation effectiveness: shedding before
46 symptom onset and shedding that might occur once isolation ends. We considered different isolation
47 end points (including 24 hours after fever resolution or 4 days after symptom onset) and assumptions
48 about the infectiousness of Ct shedding trajectories. Of the 116 household contacts with ≥ 2 positive
49 tests for longitudinal analyses, 105 (91%) experienced ≥ 1 ILI symptom. On average, children < 5 years
50 experienced greater peak shedding, longer durations of shedding, and elevated ILI symptom scores
51 compared with other age groups. Most individuals (63/105) shed $< 10\%$ of their total shed virus before
52 symptom onset, and shedding after isolation varied substantially across individuals, isolation end points,
53 and infectiousness assumptions. Our results can inform strategies to reduce transmission from
54 symptomatic individuals infected with influenza.

55

56 **Significance Statement**

57 Individuals infected with influenza are encouraged to avoid contact with others for a period following
58 symptom onset. This action should reduce the likelihood of onward transmission if infectious virus
59 shedding is associated with symptom presentation. We modeled influenza virus shedding and symptom
60 dynamics in participants of a multi-season household transmission study. On average, children < 5 years
61 shed more virus for longer durations and experienced elevated influenza-like-illness symptoms
62 compared with older age groups. Most shedding took place after symptom onset, and estimated
63 shedding that might remain after a period of avoiding contact with others depended on how the end of
64 this period was defined. Our results can help inform strategies to reduce transmission from symptomatic
65 individuals infected with influenza.

66

67 **Introduction**

68 Seasonal influenza causes substantial morbidity and mortality in the United States each year [1].
69 Measures to mitigate this burden include pharmaceutical interventions, such as vaccination, and
70 nonpharmaceutical interventions, such as case isolation. The latter is designed to reduce exposure to
71 virus shedding from symptomatic individuals, thereby reducing the potential for onward transmission.
72 The Centers for Disease Control and Prevention (CDC) recommends symptomatic individuals stay at
73 home and avoid contact with others until 24 hours after fever resolution, or for 4-5 days following
74 symptom onset if they do not experience fever [2, 3]. However, transmission will be unaffected by such
75 mitigation measures if it occurs in the absence of symptoms (for example, prior to symptom onset or

76 from asymptomatic individuals) or after the recommended duration has passed. Understanding how the
77 timing and progression of influenza symptoms relate to influenza virus shedding and transmission is
78 crucial to determining the potential impact of different strategies for reducing onward transmission
79 from symptomatic individuals [4, 5].

80 Studies of influenza transmission within households provide valuable information on the natural history
81 of infection [6]. Individual shedding and infection progression can be followed through routine PCR
82 testing of household members and recording of symptoms that arise [7, 8]. Such information can be
83 used to characterize patterns of virus shedding from asymptomatic and symptomatic individuals, and to
84 estimate household secondary attack rates and influenza vaccine effectiveness [9-13]. Individual-level
85 data can also be modeled to explore potential differences by age or vaccination status that may impact
86 the effectiveness of isolation [14-18]. Such insights have improved our understanding of effective
87 isolation measures for SARS-CoV-2 but are limited for influenza [19-21].

88 Here we modeled individual-level data from a household transmission study conducted across three
89 influenza seasons in the United States. We used cycle threshold (Ct) values obtained from real-time
90 reverse transcription quantitative PCR (RT-qPCR) testing of individual nasal swab specimens to infer
91 longitudinal virus shedding dynamics, and used symptom diaries to assess the relative timing and
92 progression of influenza-associated symptoms. We then identified differences in shedding and symptom
93 presentation by age and vaccination status, and estimated levels of pre-symptomatic shedding and
94 shedding that may remain once a mitigation measure, such as isolation, has ended. Our findings can
95 help inform effective strategies to reduce transmission from symptomatic individuals infected with
96 influenza.

97

98 **Materials and Methods**

99 **Study**

100 We conducted a case-ascertained household transmission study during the 2017-2018, 2018-2019 and
101 2019-2020 influenza seasons. Households were enrolled following the recruitment of index cases with
102 laboratory-confirmed influenza virus infection from clinics or testing sites in Wisconsin and Tennessee.
103 Households enrolled within seven days of the index illness onset date were eligible to participate and
104 followed for up to seven days after enrollment. Participants provided demographic information
105 including age and vaccination status at enrollment. Written informed consent was obtained for all
106 participants. Study protocols and procedures were reviewed by the Institutional Review Boards at the
107 Marshfield Clinic Research Institute and Vanderbilt University. CDC determined these activities were
108 conducted consistent with applicable federal law and CDC policy (see 45 C.F.R. part 46; 21 C.F.R. part
109 56). The study has been described in detail elsewhere [9, 22]; information relevant for the current
110 analysis is summarized below.

111 **Virus shedding**

112 Nasal swabs were collected daily from participants (either by study staff or self-/adult-collected) and
113 tested for influenza by real-time RT-qPCR. Testing was performed using the CDC Human Influenza Virus
114 Real-Time RT-PCR Diagnostic Panel and Influenza A/B Typing Kit at Marshfield Clinic Research Institute
115 or Vanderbilt University Medical Center. We inferred that real-time RT-qPCR Ct values were an indicator

116 of virus shedding and hereafter refer to samples with PCR positive Ct values as reflecting shed virus [23].
117 Since a positive Ct value does not necessarily reflect infectious virus, our Ct analyses relate to the total
118 viral genomic material an individual may shed, not solely that which is infectious. We explore different
119 assumptions about the relationship between Ct measurements and infectious virus in our analyses
120 below.

121 Ct values are inversely proportional to viral load such that higher Ct values reflect lower amounts of viral
122 material in a sample. Forty-five cycles were performed for each reaction and samples with Ct values <40
123 were deemed positive [24, 25]. Positive samples with values approaching 40 (e.g., values >36) were
124 repeated to ensure results were reproducible and all negative tests were assigned a value of 40. When
125 individuals had a self- and staff-collected test result on the same day, the Ct values were significantly
126 correlated (correlation = 0.6, $p < 0.0001$) and so we used the result from the self-collected swab for
127 consistency. Although Ct values can vary between laboratories, we found no evidence of systematic
128 differences in Ct dynamics by testing site (Figure S1) and thus combined data from both sites in all
129 analyses.

130 **Symptom scores**


131 Symptom diaries identifying the presence of eight possible signs and symptoms associated with
132 influenza infection (fever, cough, sore throat, runny nose, nasal congestion, fatigue, shortness of breath,
133 and wheezing) were self-/adult-administered daily (Figure 1A). We translated these diaries into a
134 quantitative score, S_{ILI} , that measured the sum of influenza-like-illness (ILI) signs or symptoms reported
135 on each day as

$$136 \quad S_{ILI} = 3 (\text{fever}) + \text{sore throat} + \text{cough},$$

137 where fever, sore throat, and cough equal 1 on days they were reported and 0 on days they were not
138 (Figure 1B). Fever was weighted more heavily as a proxy for increased clinical severity [26-28]. We also
139 defined an alternative score, S_{ANY} , that accounted for any sign or symptom assessed in the diaries. In this
140 score, shortness of breath and wheezing were more heavily weighted, in addition to fever, to include
141 greater lower respiratory tract involvement as a proxy for severity (Figure 1C) [26, 27, 29]. A value of 3
142 was assigned if at least one of fever, shortness of breath, or wheezing were reported; this value did not
143 increase if more than one was reported. Additional symptoms that were not included in the ILI
144 definition (nasal congestion, runny nose, and fatigue) were each weighted by 1/3, so that

$$145 \quad S_{ANY} = 3 (\text{fever or shortness of breath or wheezing}) + \text{sore throat} + \text{cough} + 1/3 (\text{runny nose} + \text{nasal} \\ 146 \quad \text{congestion} + \text{fatigue}).$$

147 The weights for S_{ILI} and S_{ANY} were chosen to allow for back-translation of scores to the presence or
148 absence of fever, shortness of breath, or wheezing. For example, $S_{ILI} > 2$ can only occur if fever is
149 reported and $2 \geq S_{ILI} > 1$ can only occur if cough and sore throat are reported without fever. Similarly,
150 $S_{ANY} > 3$ can only occur if fever, shortness of breath, or wheezing are among the reported symptoms; this
151 would not be the case if runny nose, nasal congestion, or fatigue were weighted by 1 instead of 1/3.
152 Finally, we defined an unweighted score, S_{UNW} , that was simply the number of signs or symptoms
153 reported on any given day [10]. We compared this with S_{ILI} and S_{ANY} to assess the sensitivity of our results
154 to the choice of scoring weights.



155
156 **Figure 1. Translation of symptom diaries to symptom scores.** (A) Symptom diary reports from a child aged <5
157 years (left panel), a child aged 5-17 (middle) and an adult aged 50+ (right). ILI signs or symptoms (fever, cough,
158 sore throat) reported on a given day are highlighted in dark grey; all other reported symptoms are shown in light
159 grey. Diary reports from (A) are translated to ILI symptom scores, S_{ILI} (B), any symptom scores, S_{ANY} (C), and
160 unweighted symptom scores, S_{UNW} (D). In (B) and (C), colors indicate the presence of fever (B), or fever, wheezing,
161 or shortness of breath (C). Note these colors have different interpretations to those in (A). ILI stands for influenza-
162 like-illness.

163

164 **Model**

165 We assume viral shedding over time within an infected individual is proportional to a continuous
166 probability distribution, $f_v(t, a_v, b_v)$. Here, a_v and b_v are the distribution parameters, and t represents days
167 since ILI symptom onset (for analysis of individuals reporting ILI symptoms); days since any symptom
168 onset (for analysis of individuals reporting any symptoms); or days since first positive test (for analysis of
169 asymptomatic individuals). To allow variation in the magnitude and timing of shedding, we model the
170 amount of virus shed at time t , $V(t)$, by

$$171 \\ 172 V(t) = h_v f_v(t - d_v, a_v, b_v),$$

173
174 where $h_v > 0$ is a magnitude scaling factor and d_v a shift in time. Similarly, we model the symptom score
175 (S_{ILI} , S_{ANY} , or S_{UNW}) of a symptomatic infected individual as

$$176 \\ 177 W(t) = h_w f_w(t - d_w, a_w, b_w),$$

178
179 where t represents days since ILI symptom onset (for S_{ILI}) or days since any symptom onset (for S_{ANY} and
180 S_{UNW}). We investigate three plausible distributions for f_v and f_w : lognormal, gamma, and Weibull
181 distributions [4, 11, 19, 30]. Since Ct values are bounded by 40 with higher values reflecting lower levels
182 of detected virus, we fit the Ct data with a transformed function, $\hat{V}(t) = 40 - V(t)$.

183

184 **Model fitting and covariate analysis**

185 Household contacts with at least two Ct values <40 were included in the modeling analysis. To mitigate
186 the impact of symptoms that were consistently reported due to causes other than influenza, we
187 discarded all data from individuals who reported symptoms on three or more days before testing
188 positive, when those days also coincided with a negative test. For analysis of symptomatic infection, we
189 included individuals whose first swab (positive or negative) was on or before symptom onset, and $t = 0$
190 anchored all trajectories at symptom onset. For analysis of asymptomatic infection, we could not use
191 time since symptom onset as a common anchor point. We therefore only included individuals with
192 ‘incident’ infection (i.e., those with a recorded negative test before their first positive test). This allowed
193 us to use time since first positive test as a common anchor point that was at, or near, the onset of virus
194 shedding (Figure S2).

195 We fit $\hat{V}(t)$ and $W(t)$ to the Ct and symptom score data, respectively, using a nonlinear mixed effects
196 framework [31, 32]. We assumed both variables were normally-distributed with constant error terms,
197 and ensured model residuals were normally-distributed using the Shapiro-Wilk test [33]. Each parameter
198 was assigned a fixed effect and an individual-level random effect; the latter captured variation between
199 participants. We assumed a , b and h were lognormally distributed to ensure positivity, and d was
200 normally distributed to allow positive or negative shifts in time. All parameters were assumed to be
201 independent, and we explored models that stratified one or more parameters by candidate covariates
202 for age group, vaccination status, virus type and season. The importance of each covariate-parameter
203 relationship was evaluated using ANOVA [31, 32].

204 The fit of each candidate model (lognormal, gamma, or Weibull) was compared using Akaike
205 Information Criterion (AIC), where lower AIC values reflect greater statistical support [34]. For the model
206 with lowest AIC, we simulated Ct and symptom trajectories for each individual using the fitted
207 parameter estimates. We then calculated key summary metrics, including the duration of shedding (or
208 duration of symptoms), the timing of peak shedding (or timing of peak symptom scores), and the area
209 under each curve. We tested for associations between these summary metrics and each candidate
210 covariate (listed above) using the non-parametric Kruskal-Wallis test and controlled the false-discovery
211 rate using the Benjamini-Hochberg correction. Further details on summary metric calculations are
212 provided in the Supplementary Information.

213 Due to sample size, we did not perform additional stratifications by multiple covariates when testing for
214 associations with the summary metrics described above. Instead, to distinguish covariates with the
215 greatest independent influence on trajectory dynamics from those acting primarily through collinearity
216 with other covariates, we performed hierarchical partitioning [35, 36]. Hierarchical partitioning provides
217 a systematic way to assess the independent influence of a particular covariate on a dependent variable,
218 after accounting for the effects of other covariates (additional details are provided in the Supplementary
219 Information). Statistical significance was assessed by comparing results to those obtained through 250
220 random permutations of the covariates.

221

222 **Implications for isolation impact**

223 We estimated the extent of shedding that would occur before and after a period of isolation by first
224 calculating the proportion of total shedding that had occurred up to any given day, t , as $F_v(t)$, where F_v is
225 the cumulative distribution of the best-fitting model for viral shedding, f_v . The proportion of shedding
226 that would have occurred prior to symptom onset and isolation (i.e., pre-symptomatic shedding) is $F_v(0)$,
227 and the proportion of shedding that would still occur if isolation ended on day t_i is $1 - F_v(t_i)$. These
228 estimates account for the magnitude of shedding, in addition to the duration, and are thus more
229 informative than estimates of shedding duration alone.

230 The value of t_i represents the duration of isolation and was assigned for each individual to align with
231 CDC recommendations for staying at home: t_i was set to 24 hours after fever resolution for those who
232 experienced fever, and after 4 (or 5) days post symptom onset for those who did not experience fever
233 [2, 3]. The 'back translation' property of S_{ILI} was used to identify individuals who experienced fever (i.e.,
234 attained $S_{ILI} > 2$) and to determine the time of fever resolution (i.e., when the fitted S_{ILI} trajectory first
235 decreased below 2 after attaining its peak). Note that the fitted S_{ILI} trajectories are a continuous
236 representation of a discrete scoring system and so although fever is assigned a value of 3 in S_{ILI} , anything
237 greater than 2 (i.e. anything above the score assigned for cough + sore throat) is interpreted as possible
238 fever for the purpose of this analysis. In general, $S_{ILI} > 2$ was a faithful indicator of those who experienced
239 fever (Supplementary Information).

240 Given that Ct values reflect total virus genomic material in a specimen rather than infectious shed virus
241 (i.e., virus with onward transmission potential) we also sought to translate our estimates of viral
242 shedding remaining following the end of isolation to estimates of infectious shedding, or transmission
243 potential, remaining. First, we defined several candidate functions, $g_v(t)$, to describe the proportion of
244 Ct-measured virus that is infectious at any given time. These included (i) a worst-case scenario in which

245 100% of Ct-measured virus is infectious for the entire duration of shedding; (ii) a best-case scenario in
246 which 100% of Ct-measured virus is infectious until 4 days post symptom onset, and then 0% for the
247 remainder; and (iii) an intermediate scenario in which the infectious percentage of Ct-measured virus
248 decreases linearly from 0 to 7 days following symptom onset [10, 30, 37, 38]. These functions were
249 designed for illustrative purposes and are not an exhaustive list of possible infectious virus dynamics.
250 We then estimated the percentage of transmission potential remaining at time t_i as $(1 - G_f(t_i)) \times 100\%$,
251 where $G_f(t)$ is the cumulative distribution of $g_v(t) \times f_v(t)$. Assuming secondary infections caused by an
252 infectious individual are distributed in proportion to their infectious shedding distribution, the number
253 of secondary infections generated following the end of isolation can be approximated as $R_t \times (1 - G_f(t_i))$,
254 where R_t is the effective reproduction number.

255 Model fitting and parameter estimation were conducted using Monolix 2021R2 and the
256 `lixoftConnectors` and `Rsmplx` packages in R 4.0.3 (Table S1) [39-42]. Downstream analyses and
257 plotting were conducted with the `hier.part`, `tidyverse`, `here`, `patchwork`, `ggpubr` and
258 `scico` packages [43-48]. Further methodological details are provided in the Supplementary
259 Information.


260

261 Results

262 We identified 116 household contacts with PCR-detectable influenza virus infection and at least two Ct
263 values <40 (Figure S2). Of these, 108 (93%) reported at least one symptom and 105 (91%) reported at
264 least one ILI symptom (fever, cough, or sore throat) during study follow-up (Table S2). Most infections
265 were caused by influenza A viruses (86/116; 74%), and 48 (41%) individuals were vaccinated with the
266 current season's influenza vaccine. Additional characteristics partitioned by age and vaccination status
267 or influenza-like-illness (ILI) symptoms are provided in Table S3.


268 For individuals experiencing at least one ILI symptom ($N = 105$), a Weibull distribution with shape
269 parameter (a) and magnitude parameter (h) modified by age provided the best-fit to the Ct data,
270 whereas a Weibull distribution with scale parameter (b) modified by age and magnitude modified by
271 vaccination status provided the best-fit to the S_{ILI} scores (Table S4, Figures S3-S5). Results were similar
272 when fitting to the Ct and S_{ANY} (or S_{UNW}) observations from those who reported any symptom ($N = 108$;
273 Table S5, Figures S5-S8). These findings suggest viral shedding dynamics differ by age, and symptom
274 score dynamics differ by age and vaccination status.

275 To investigate further, we tested whether age or vaccination status were associated with any trajectory
276 summary metrics. First, we found that young children (aged <5 years) shed significantly more total virus
277 ($p < 0.0001$), had higher peaks in shedding ($p < 0.0001$), and had longer durations of shedding ($p <$
278 0.0001) relative to other age groups (Figure 2, Figure S9). Children aged <5 years also experienced higher
279 peaks in S_{ILI} than adults aged ≥ 50 years and shorter durations of S_{ILI} than adults ≥ 18 years (Figure S10, p
280 < 0.01). Conversely, there were no differences in peak symptom score by age when using S_{ANY} or S_{UNW}
281 (Figures S11-12). This was likely driven by the contribution of wheezing and shortness of breath to S_{ANY}
282 and S_{UNW} : older individuals, who were less likely to experience fever (Figure S10), were still assigned
283 higher symptom scores if they reported these additional symptoms (Figure S11). Thus, the S_{ANY} or S_{UNW}
284 scores may be more sensitive to symptom progression in older individuals.



285
286 **Figure 2. Children aged <5 years shed more virus than other age groups.** Associations between age group and
287 viral shedding summary metrics: (A) day of shedding clearance relative to ILI onset; (B) day of shedding onset
288 relative to ILI onset; (C) day of peak shedding relative to ILI onset; (D) duration of shedding in days; (E) Peak value
289 of shedding attained (transformed as 40 – Ct); and (F) total virus shed, as measured by the area under the fitted
290 shedding curve. ILI represents influenza-like-illness and AUC represents the area under the curve. *p < 0.05, **p
291 < 0.01, ***p < 0.001, ****p < 0.0001.

292
293 There were no significant associations between vaccination status and the viral shedding metrics (Figure
294 S13). This is unlikely to be confounded by age as the hierarchical partitioning analysis also found no
295 independent effect of vaccination status on the shedding summary metrics (Figure S14). In contrast,
296 vaccinated individuals experienced lower total S_{ILI} scores ($p = 0.02$) than unvaccinated individuals (Figure
297 3). Hierarchical partitioning confirmed that this observation was unlikely to be confounded by age
298 (Figure S14). Results were similar with S_{UNW} , although vaccinated individuals also experienced shorter
299 durations in S_{UNW} symptom scores ($p < 0.01$) (Figure S15). Conversely, we found no systematic
300 relationship between the summary metrics and vaccination status with S_{ANY} (Figure S16).




301
302 **Figure 3. Vaccinated individuals experience lower S_{ILI} scores.** Associations between vaccination status and S_{ILI}
303 summary metrics: (A) time of peak S_{ILI} score relative to days since ILI onset; (B) duration of S_{ILI} score in days; (C)
304 peak S_{ILI} score attained; and (D) total S_{ILI} score, as measured by the area under the fitted S_{ILI} symptom curve. ILI
305 represents influenza-like-illness and AUC represents the area under the fitted symptom score curve. * $p < 0.05$, ** p
306 < 0.01 , *** $p < 0.001$, **** $p < 0.0001$.

307
308 Among the other covariates tested (virus type and season), we found an association between season
309 and the time of shedding: infections from 2017-2018 experienced later peaks in shedding ($p < 0.01$) than
310 infections from 2018-2019 and 2019-2020 (Figure S17A). However, the hierarchical partitioning analysis
311 suggested this association may be confounded by age (Figure S14), since children < 5 were not
312 represented in the 2017-18 data (Figure S1) and may experience earlier peaks in shedding (Figure 2). We
313 also did not detect any associations between shedding among individuals who reported higher ILI scores
314 (peak $S_{ILI} > 2$) and those who reported lower scores (peak $S_{ILI} \leq 2$) (Figure S17B).


315 Finally, we fit Ct data from 71 individuals with incident infection to compare shedding dynamics during
316 asymptomatic and symptomatic infection (Figures S2 and S18). Asymptomatic individuals experienced
317 substantially shorter durations of shedding than symptomatic individuals, in addition to lower peak and
318 total shedding levels (Figure S19). We did not include additional covariates or formally test these results
319 due to the sample size (8 asymptomatic infections and 63 symptomatic infections).

320
321 **Implications for isolation impact**
322 Any shedding that occurs prior to symptom onset ('pre-symptomatic shedding') will reduce the
323 effectiveness of isolation measures. In this study, we estimated that most individuals (60%; 63/105)
324 shed less than 10% of their total virus before the onset of an ILI symptom, although 15% (16/105) shed
325 more than 50% before onset (Figure 4A). Individuals in the latter group had no characteristic in common
326 with respect to age, vaccination status, type of infecting virus, or season of infection (Table S6). Across
327 all individuals there was a nonsignificant reduction in average pre-symptomatic shedding among adults
328 ≥ 18 years compared to children < 18 years ($p = 0.2$; Figure 4B), and no relationship with vaccination
329 status (Figure 4C).




330
331 **Figure 4. Pre-symptomatic shedding is heterogeneous.** (A) Distribution of pre-symptomatic shedding across all
332 individuals with ILI symptoms (N = 105). (B) Association between pre-symptomatic shedding and age group. (C)
333 Association between pre-symptomatic shedding and vaccination status. Pre-symptomatic shedding was estimated
334 as the percentage of total virus shedding that occurred prior to ILI symptom onset. ILI stands for influenza-like-
335 illness. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001.

336 In addition to pre-symptomatic shedding, shedding may also persist after isolation has ended. Current
337 recommendations advise symptomatic individuals infected with influenza viruses to stay at home and
338 avoid contact with others until 24 hours after fever resolution, or 4-5 days following symptom onset if
339 they do not experience fever [2, 3]. We henceforth refer to the former as a ‘fever-based’ strategy and
340 the latter as a ‘duration-based’ strategy. For those following the fever-based strategy (i.e., those who
341 experienced fever), we calculated the percentage of shedding remaining one day post fever resolution
342 (Figures 5A-B). For those who did not experience fever and instead followed the duration-based
343 strategy, we calculated the percentage of shedding remaining after four days post ILI symptom onset
344 (i.e., on day five post ILI symptom onset; Figure 5C). We considered shedding remaining after five days
345 post ILI symptom onset in sensitivity analyses (Figure S20). We then combined estimates across all
346 individuals to understand post-isolation shedding distributions at the population-level, if isolation
347 practices aligned with current recommendations for staying at home. In this study, the median
348 percentage of shedding remaining after isolation was 1-29% across age and vaccination groups, and
349 there was substantial inter-individual variation in shedding remaining and in isolation duration (Figures
350 5D-E). Notably, adults ≥ 50 years were less likely to experience fever and thus more likely to isolate for a
351 fixed duration of four days. We also identified eight individuals with fever would have isolated for over
352 six days. If all symptomatic participants instead followed the four-day duration-based strategy (i.e.,
353 everyone isolated for four days following ILI symptom onset), average estimates of shedding remaining
354 were equal to, or lower than, the combination of fever-based and duration-based strategies, and inter-
355 individual variation was greatly reduced (Figure 5F).



356
 357 **Figure 5. Duration-based isolation strategies are effective in reducing shedding remaining after isolation from**
 358 **symptomatic individuals.** (A-B) Example ILI symptom (A) and shedding remaining (B) trajectories from a child aged
 359 5-17 years following a fever-based isolation strategy. The dashed vertical line represents the time of fever
 360 resolution, and the solid vertical line represents the end of recommended isolation. (C) Corresponding shedding
 361 remaining trajectory for the same child following a duration-based isolation strategy. (D-E) Estimates of shedding
 362 remaining (D) and duration of isolation in days (E) assuming isolation practices align with current
 363 recommendations for staying at home (i.e., a mixture of fever-based and duration-based strategies). (F) Estimates
 364 of shedding remaining assuming all individuals follow a four day duration-based isolation strategy, including those
 365 who experience fever. Estimates in (E, F) are stratified by age and vaccination status. Points represent the median
 366 within each stratification and error bars are the 90th percentiles.

367



368
369 **Figure 6. Framework for translating viral shedding to estimates of onward transmission potential.** (A) Example
370 functions for the percentage of shed virus that is infectious at any time, $g_v(t)$. (B) Example application of functions
371 for $g_v(t)$ shown in (A) to the fitted Ct trajectory of the individual shown in Figure 5B. The worst-case scenario
372 reflects the original fitted Ct trajectory. (C) Corresponding estimates of the percentage of infectious shedding
373 remaining for the same individual and the same functions for $g_v(t)$ shown in (A). The grey vertical line indicates the
374 end of a four day duration-based isolation strategy. (D) Estimates of transmission potential remaining across all
375 symptomatic individuals following the end of a four day duration-based isolation strategy, expressed as the
376 number of secondary infections caused by each individual when $R_t = 1.2$.

377 Ct trajectories reflect the dynamics of total viral RNA in a sample rather than infectious virus (i.e., virus
378 with onward transmission potential). We therefore explored how estimates of shedding remaining could
379 be translated to estimates of infectious shedding, or transmission potential, remaining by defining three
380 candidate functions, $g_v(t)$, to describe the proportion of Ct-measured virus that is infectious at any given
381 time: (i) a worst-case scenario in which all shed virus was assumed infectious; (ii) a best-case scenario in
382 which all shed virus was infectious until four days post ILI symptom onset and 0% was infectious
383 following that time; and an intermediate scenario in which the infectiousness of shed virus decayed
384 linearly from 0-7 days post ILI symptom onset (Figures 6A-B) [10, 30, 37, 38]. Unsurprisingly, estimates
385 of infectious shedding remaining depend on the assumed infectiousness function, $g_v(t)$: for an example
386 individual ending isolation after four days post ILI symptom onset, the percentage of infectious virus
387 remaining was 0%, 5% and 17% in the best, intermediate, and worst-case scenarios, respectively (Figure
388 6C). Translating these estimates to the potential number of secondary infections generated per infected
389 individual following the end of a four-day duration-based isolation strategy (assuming $R_t = 1.2$ [49])
390 resulted in projections ranging from 0–0.6 across participants (Figure 6D). Given the strong assumptions
391 underlying each infectiousness function, these results are presented for illustration purposes only.

392

393 **Discussion**

394 The effectiveness of isolation strategies for individuals with symptomatic influenza virus infection
395 depends in part on the dynamics of virus shedding in relation to symptom timing and severity. We fit
396 nonlinear mixed-effects models to data from an influenza household transmission study and identified
397 differences in shedding by age and symptom scores by age and vaccination status. We also found
398 relatively low levels of pre-symptomatic, asymptomatic, and post-isolation shedding, which could have
399 important implications for the effectiveness of influenza control through isolation.

400 Young children are thought to play a central role in influenza transmission within households due to
401 increased susceptibility and infectivity [6, 16, 50]. Here, we found that young children aged <5 years
402 shed more virus than all other age groups and experienced higher peaks and longer durations of
403 shedding. A previous study also found children (aged ≤ 18 years) experienced longer durations of
404 shedding than adults, although there was no difference in shedding levels at symptom onset [30]. The
405 difference between the latter result and our identified association with peak shedding levels may be
406 influenced by how age groups were partitioned. The significantly higher peak shedding in children aged
407 <5 years found in this study would have likely been obscured if young children and adolescents (aged 5-
408 17 years) had been analyzed together as previously reported [30]. In addition to differences in shedding
409 dynamics, we identified age-related differences in symptom duration and severity. The former increased
410 with age and has been reported previously [7]. The latter was influenced by the chosen symptom score:
411 S_{LI} scores tended to decrease with age whereas S_{ANY} and S_{UNW} scores did not. This is likely due to the
412 inclusion of wheezing and shortness of breath in S_{ANY} and S_{UNW} , which may offer a more sensitive
413 description of symptom burden in older adults for whom fever is less common.

414 In contrast to age, we found no difference in shedding dynamics by vaccination status. This suggests
415 vaccination did not reduce transmission potential in participants with breakthrough infections. Our
416 finding aligns with results from a previous household transmission study [37] and can help inform
417 mathematical modeling studies which must typically make assumptions regarding the infectiousness of
418 breakthrough infections in vaccinated individuals relative to unvaccinated individuals. Despite similar
419 shedding profiles, vaccinated infected participants did experience lower total S_{LI} scores than their
420 unvaccinated counterparts. This effect was likely driven by a reduction in fever, given that the
421 association was present with S_{UNW} (which also includes an independent term for fever) but not with S_{ANY}
422 (in which wheezing or shortness of breath can compensate for the absence of fever). Our results are
423 consistent with a meta-analysis that found influenza-infected vaccinated individuals were significantly
424 less likely to develop fever than infected unvaccinated individuals, but equally likely to develop other
425 symptoms including cough, headache, sore throat, wheezing, fatigue, and nasal congestion [51]. More
426 generally, our findings highlight the importance of considering multiple scoring metrics when analyzing
427 individual symptom dynamics.

428 In addition to identifying individual differences in shedding and symptom dynamics, we explored the
429 potential impact of these dynamics on the effectiveness of influenza isolation measures by estimating
430 levels of pre-symptomatic and post-isolation shedding from symptomatic individuals, and by comparing
431 shedding dynamics of symptomatic individuals with those of asymptomatic individuals (who would not
432 be reached by isolation recommendations). We found pre-symptomatic shedding levels were relatively
433 low for most participants, consistent with previous work [52]. However, 15% experienced more than
434 50% of their shedding prior to symptom onset, suggesting isolation could miss a substantial proportion
435 of transmission in a small fraction of individuals. With respect to post-isolation shedding, although
436 longer durations of isolation will generally favor greater reductions in shedding, this effect must be

437 balanced with the financial and emotional burdens associated with adhering to such measures for
438 prolonged periods [53]. Notably, we found that isolation of all symptomatic persons for four days post
439 ILI symptom onset, regardless of the presence of fever, may be as effective in reducing shedding
440 compared with a strategy informed by current recommendations for staying at home (which had
441 different recommendations for people experiencing fever and would have required some participants to
442 isolate for six days or more). Finally, we found that asymptomatic infections were rare and shed
443 substantially less virus, for shorter periods of time, than symptomatic infections. Although the sample
444 size was small, these findings support previous analyses [13, 52] and suggest that transmission from
445 symptomatic individuals could comprise the majority of seasonal influenza transmission. There may also
446 be implications for mathematical modeling studies which often assume symptomatic and asymptomatic
447 infections are equally transmissible [54]. Overall, our results suggest prompt isolation of symptomatic
448 individuals could be an effective measure for influenza control due to generally low levels of pre-
449 symptomatic transmission, virus shedding post-isolation, and shedding from asymptomatic individuals.

450 There are several limitations to this study. First, shedding trajectories were fit to Ct values which detect
451 total viral RNA in a sample rather than infectious shed virus. Quantifying the latter would require
452 additional data, such as viral culture, that were not available for this study. Given that influenza viral
453 culture measures decline more rapidly than total shed virus [37], our estimates of pre-symptomatic and
454 post-isolation shedding are likely upper bounds on infectious virus shedding. Although these can still be
455 useful for planning purposes [23], modeling dynamics of infectious virus, and assessing whether these
456 differ by age and/or other covariates, is a critical avenue for future work. Similarly, when estimating the
457 number of secondary infections that occur after isolation, we assumed these were distributed in
458 proportion to an individual's estimated infectious shedding distribution. Although this may be largely
459 consistent with transmission in community settings, where isolation guidance is most applicable, it does
460 not account for typically higher rates of exposure and susceptible depletion that can occur within
461 households.

462 Second, we used symptom diaries to quantify symptom onset and severity, which may include reports of
463 symptoms caused by factors other than influenza virus infection (henceforth referred to as non-specific
464 symptoms). For example, individuals may be more likely to report fatigue and runny nose which have
465 many other causes. Reporting of non-specific symptoms may contribute to the high frequency of
466 symptomatic infection identified in this study compared to others [55-57]. In addition, our estimates of
467 pre-symptomatic shedding (which depend on the time of reported symptom onset) may be
468 underestimated if non-specific symptoms were reported before influenza-specific symptoms. To
469 mitigate these impacts, we used definitions that closely track influenza related symptoms (for example,
470 ILI), and excluded data from individuals who reported symptoms on three or more days with a
471 corresponding negative influenza test, before their first positive test. However, our symptom score
472 trajectories may still be biased towards earlier and/or higher values.

473 Finally, we used a phenomenological approach to fit the functional forms of the shedding and symptom
474 score data, rather than developing a mechanistic model to explain underlying virus replication and cell
475 infection dynamics [58-61]. This choice was motivated by data availability: fitting an appropriate and
476 identifiable mechanistic model for influenza virus infection requires information on viral load and
477 various immune cell populations that were not captured in this study. Although our approach cannot
478 estimate within-host parameters such as viral growth rates and infected cell lifetimes, we are still able to

479 capture shedding and symptoms score trajectories and explore differences in their relative timing and
480 magnitude.

481 In this work we have illustrated how phenomenological modeling of data routinely collected during
482 household transmission studies can elucidate virus shedding and symptom dynamics within individuals
483 and identify differences by age and vaccination status. Our framework can also be used to estimate the
484 impact of isolation in reducing influenza virus transmission, and thus inform effective strategies for
485 influenza isolation.

486

487 **Acknowledgements:** The authors would like to thank Alicia Fry, Scott Blackwell, Emma Pedigree-
488 Cannon, Holly Morse, Megan Eluhu, Emily Jookar, Christina Khouri, Robert Lyons, Carleigh Frazier, Janika
489 Raynes, Preston Gibson, Karen Malone, Sarah Davis, Olivia Doak, Judy King, and the study participants.

490

491 References

- 492 1. CDC. *Past Seasons Estimated Influenza Disease Burden*. 2023 [cited 2023 April 17]; Available
493 from: <https://www.cdc.gov/flu/about/burden/index.html>.
- 494 2. CDC, *Flu: What To Do If You Get Sick*. 2022; Available from:
495 <https://www.cdc.gov/flu/treatment/takingcare.htm>.
- 496 3. CDC. *Stay Home When You Are Sick*. 2020; Available from:
497 <https://www.cdc.gov/flu/business/stay-home-when-sick.htm>.
- 498 4. Johansson, M.A., et al., *SARS-CoV-2 Transmission From People Without COVID-19 Symptoms*.
499 *JAMA Netw Open*, 2021. **4**(1): p. e2035057.
- 500 5. Fraser, C., et al., *Factors that make an infectious disease outbreak controllable*. *Proc Natl Acad*
501 *Sci U S A*, 2004. **101**(16): p. 6146-51.
- 502 6. Tsang, T.K., et al., *Household Transmission of Influenza Virus*. *Trends Microbiol*, 2016. **24**(2): p.
503 123-133.
- 504 7. Petrie, J.G., et al., *Influenza transmission in a cohort of households with children: 2010-2011*.
505 *PLoS One*, 2013. **8**(9): p. e75339.
- 506 8. Xu, C., et al., *Comparative Epidemiology of Influenza B Yamagata- and Victoria-Lineage Viruses*
507 *in Households*. *Am J Epidemiol*, 2015. **182**(8): p. 705-13.
- 508 9. Rolfes, M.A., et al., *Household Transmission of Influenza A Viruses in 2021-2022*. *JAMA*, 2023.
509 **329**(6): p. 482-489.
- 510 10. Cowling, B.J., et al., *Comparative epidemiology of pandemic and seasonal influenza A in*
511 *households*. *N Engl J Med*, 2010. **362**(23): p. 2175-2184.
- 512 11. Levy, J.W., et al., *The serial intervals of seasonal and pandemic influenza viruses in households in*
513 *Bangkok, Thailand*. *Am J Epidemiol*, 2013. **177**(12): p. 1443-51.
- 514 12. Malosh, R.E., et al., *Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8*
515 *Years: Is There Evidence of Indirect Protection?* *Clin Infect Dis*, 2021. **73**(7): p. 1248-1256.
- 516 13. Ip, D.K., et al., *Viral Shedding and Transmission Potential of Asymptomatic and*
517 *Paucisymptomatic Influenza Virus Infections in the Community*. *Clin Infect Dis*, 2017. **64**(6): p.
518 736-742.
- 519 14. Lau, M.S., et al., *Inferring influenza dynamics and control in households*. *Proc Natl Acad Sci U S A*,
520 2015. **112**(29): p. 9094-9.

- 521 15. Cauchemez, S., et al., *Determinants of influenza transmission in South East Asia: insights from a*
522 *household cohort study in Vietnam*. PLoS Pathog, 2014. **10**(8): p. e1004310.
- 523 16. Cauchemez, S., et al., *A Bayesian MCMC approach to study transmission of influenza: application*
524 *to household longitudinal data*. Stat Med, 2004. **23**(22): p. 3469-87.
- 525 17. Tsang, T.K., et al., *The effect of variation of individual infectiousness on SARS-CoV-2 transmission*
526 *in households*. Elife, 2023. **12**.
- 527 18. Tsang, T.K., et al., *Association between antibody titers and protection against influenza virus*
528 *infection within households*. J Infect Dis, 2014. **210**(5): p. 684-92.
- 529 19. He, X., et al., *Temporal dynamics in viral shedding and transmissibility of COVID-19*. Nat Med,
530 2020. **26**(5): p. 672-675.
- 531 20. Hakki, S., et al., *Onset and window of SARS-CoV-2 infectiousness and temporal correlation with*
532 *symptom onset: a prospective, longitudinal, community cohort study*. Lancet Respir Med, 2022.
533 **10**(11): p. 1061-1073.
- 534 21. WHO. *Criteria for releasing COVID-19 patients from isolation*. 2020; Available from:
535 [https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-](https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation)
536 [from-isolation](https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation).
- 537 22. Mellis, A.M., et al., *SARS-CoV-2 Virus Dynamics in Recently Infected People-Data From a*
538 *Household Transmission Study*. J Infect Dis, 2022. **226**(10): p. 1699-1703.
- 539 23. Tom, M.R. and Mina, M.J., *To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold*
540 *Value*. CID, 2020. **71**(16): p. 2252-2254.
- 541 24. Ellis, J., et al., *Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses*.
542 Euro Surveill, 2009. **14**(22): p. 1-3.
- 543 25. Liao, R.S., et al., *Comparison of a laboratory-developed RT-PCR and the CDC RT-PCR protocol*
544 *with rapid immunodiagnostic testing during the 2009 H1N1 influenza A pandemic*. Diagn
545 Microbiol Infect Dis, 2011. **70**(2): p. 236-9.
- 546 26. Hsiao, A., et al., *Retrospective study of the use of an influenza disease two-tiered classification*
547 *system to characterize clinical severity in US children*. Hum Vaccin Immunother, 2020. **16**(8): p.
548 1753-1761.
- 549 27. Heikkinen, T., et al., *Clinical and socioeconomic impact of moderate-to-severe versus mild*
550 *influenza in children*. Eur J Clin Microbiol Infect Dis, 2016. **35**(7): p. 1107-13.
- 551 28. Bilcke, J., S. Coenen, and P. Beutels, *Influenza-like-illness and clinically diagnosed flu: disease*
552 *burden, costs and quality of life for patients seeking ambulatory care or no professional care at*
553 *all*. PLoS One, 2014. **9**(7): p. e102634.
- 554 29. CDC. *Flu Symptoms & Complications*. 2022 [cited 2023 8 June]; Available from:
555 <https://www.cdc.gov/flu/symptoms/symptoms.htm>.
- 556 30. Tsang, T.K., et al., *Influenza A Virus Shedding and Infectivity in Households*. J Infect Dis, 2015.
557 **212**(9): p. 1420-8.
- 558 31. Lavielle, M. and F. Mentre, *Estimation of population pharmacokinetic parameters of saquinavir*
559 *in HIV patients with the MONOLIX software*. J Pharmacokinet Pharmacodyn, 2007. **34**(2): p. 229-
560 49.
- 561 32. Chan, P.L., et al., *The use of the SAEM algorithm in MONOLIX software for estimation of*
562 *population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in*
563 *asymptomatic HIV subjects*. J Pharmacokinet Pharmacodyn, 2011. **38**(1): p. 41-61.
- 564 33. Shapiro, S.S. and M.B. Wilk, *An analysis of variance test for normality (complete samples)*.
565 Biometrika, 1965. **52**(3-4): p. 591-611.
- 566 34. Burnham, K.P. and D.R. Anderson, *Multimodel Inference: Understanding AIC and BIC in Model*
567 *Selection*. Sociological Methods & Research, 2004. **33**(2): p. 261-304.

- 568 35. MacNally, R., *Regression and model-building in conservation biology, biogeography and ecology: The distinction between – and reconciliation of – ‘predictive’ and ‘explanatory’ models.* Biodiversity and Conservation, 2000. **9**: p. 655-671.
- 570
- 571 36. Chevan, A. and M. Sutherland, *Hierarchical partitioning.* The American Statistician, 1991. **45**: p. 90-96.
- 572
- 573 37. Suess, T., et al., *Comparison of shedding characteristics of seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007-2011.* PLoS One, 2012. **7**(12): p. e51653.
- 574
- 575 38. Ip, D.K.M., et al., *The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections.* Clin Infect Dis, 2016. **62**(4): p. 431-437.
- 576
- 577
- 578 39. Team, R.C., *R: A Language and Environment for Statistical Computing.* 2020: R Foundation for Statistical Computing.
- 579
- 580 40. Lavielle, M., *Rsmxl: R Speaks ‘Monolix’.* R package version 5.0.1, 2022.
- 581 41. LIXOFT, *lixoftConnectors: R connectors for Lixoft Suite (@Lixoft).* R package version 2021.2, 2022.
- 582 42. Lixoft. *Monolix.* 2021; Available from: <https://lixoft.com/products/monolix/>.
- 583 43. Kassambara, A., *ggpubr: ‘ggplot2’ Based Publication Ready Plots.* R package version 0.4.0, 2020.
- 584 44. Pedersen, T.L., *patchwork: The Composer of Plots.* R package version 1.1.1, 2020.
- 585 45. Pedersen, T.L. and F. Cramer, *scico: Colour Palettes Based on the Scientific Colour-Maps.* R package version 1.3.0, 2021.
- 586
- 587 46. Wickham, H., et al., *Welcome to the tidyverse.* Journal of Open Software, 2019. **4**(43): p. 1686.
- 588 47. Müller, K., *here: A Simpler Way to Find Your Files.* R package version 1.0.1, 2020.
- 589 48. MacNally, R. and C.J. Walsh, *Hierarchical partitioning public-domain software.* Biodiversity and Conservation, 2004. **13**: p. 659-660.
- 590
- 591 49. Biggerstaff, M., et al., *Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature.* BMC Infectious Diseases, 2014. **14**: p. 480.
- 592
- 593
- 594 50. Viboud, C., et al., *Risk factors of influenza transmission in households.* Br J Gen Pract, 2004. **54**(506): p. 684-9.
- 595
- 596 51. Pan, Y., et al., *Meta-analysis of whether influenza vaccination attenuates symptom severity in vaccinated influenza patients.* Public Health Nursing, 2022. **39**(2): p. 509-516.
- 597
- 598 52. Lau, L.L.H., et al., *Viral Shedding and Clinical Illness in Naturally Acquired Influenza Virus Infections.* The Journal of Infectious Diseases, 2010. **201**(10): p. 1509-1516.
- 599
- 600 53. Pfefferbaum, B. and C.S. North, *Mental Health and the Covid-19 Pandemic.* New England Journal of Medicine, 2020. **383**(6): p. 510-512.
- 601
- 602 54. Montgomery, M.P., et al., *The role of asymptomatic infections in influenza transmission: what do we really know.* Lancet Inf Dis, 2023. DOI: 10.1016/S1473-3099(23)00619-9.
- 603
- 604 55. Leung, N.H.L., et al., *The Fraction of Influenza Virus Infections That Are Asymptomatic. A Review and Meta-analysis.* Epidemiology, 2015. **26**(6): p. 862-872.
- 605
- 606 56. Cohen, C., et al., *Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study.* The Lancet Global Health, 2021. **9**(6): p. e863-e874.
- 607
- 608
- 609 57. Newall, A.T., et al., *Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States.* Vaccine, 2018. **36**(39): p. 5910-5915.
- 610
- 611 58. Asher, J., et al., *Novel modelling approaches to predict the role of antivirals in reducing influenza transmission.* PLoS Comput Biol, 2023. **19**(1): p. e1010797.
- 612
- 613 59. Saenz, R.A., et al., *Dynamics of influenza virus infection and pathology.* J Virol, 2010. **84**(8): p. 3974-83.
- 614

- 615 60. Baccam, P., et al., *Kinetics of influenza A virus infection in humans*. J Virol, 2006. **80**(15): p. 7590-
616 9.
617 61. Dobrovolny, H.M., et al., *Assessing mathematical models of influenza infections using features of*
618 *the immune response*. PLoS One, 2013. **8**(2): p. e57088.
619